Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 3, 2020
Daily News
March 3, 2020
- Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
- Takeda’s ALK Drug Alunbrig Earns EU Backing for 1st Line NSCLC
March 3, 2020
- Japan Panel Says No to Nonprescription Switch for Domperidone, Menatetrenone; Decision Now Up for Public Comments
March 3, 2020
- Takeda to Sell Latin American Non-Core Assets to Brazil’s Hypera Pharma
March 3, 2020
- MHLW to Announce New NHI Prices on March 5
March 3, 2020
- Senior Vice Health Minister, Parliamentary Secretary Test Negative for Coronavirus
March 3, 2020
- Otsuka to Copromote Novartis’ Approval-Pending Entresto in Japan
March 3, 2020
- Sumitomo Dainippon Invests in Oncology Venture Fund
March 3, 2020
- Fujifilm’s US Subsidiary to Launch New iPS Cell Production Facility
March 3, 2020
- Toho Forges Capital Alliance with Kringle Pharma for Hepatocyte Growth Factor Development
March 3, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…